Your browser is no longer supported. Please, upgrade your browser.
Genmab A/S
Index- P/E- EPS (ttm)- Insider Own- Shs Outstand653.40M Perf Week-6.82%
Market Cap25.25B Forward P/E5.00 EPS next Y7.73 Insider Trans- Shs Float646.73M Perf Month-13.03%
Income- PEG- EPS next Q1.05 Inst Own7.04% Short Float0.22% Perf Quarter-18.74%
Sales10.80B P/S2.34 EPS this Y380.00% Inst Trans- Short Ratio3.98 Perf Half Y-3.90%
Book/sh- P/B- EPS next Y46.40% ROA- Target Price46.36 Perf Year4.07%
Cash/sh- P/C- EPS next 5Y27.00% ROE- 52W Range30.10 - 49.07 Perf YTD-4.97%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-20.56% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low29.50% ATR1.11
Employees871 Current Ratio- Sales Q/Q77.20% Oper. Margin- RSI (14)34.24 Volatility2.68% 2.03%
OptionableYes Debt/Eq- EPS Q/Q307.40% Profit Margin- Rel Volume1.47 Prev Close38.64
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume359.50K Price38.98
Recom2.40 SMA20-8.70% SMA50-10.31% SMA200-4.66% Volume45,748 Change0.88%
Sep-16-21Downgrade Jefferies Buy → Hold $45.50 → $48
Sep-07-21Downgrade Morgan Stanley Equal-Weight → Underweight $37
Aug-24-21Downgrade H.C. Wainwright Buy → Neutral $47
Apr-20-21Initiated Deutsche Bank Buy
Jan-19-21Downgrade Morgan Stanley Overweight → Equal-Weight $41
Sep-23-20Downgrade Bryan Garnier Neutral → Sell
Sep-08-20Initiated SVB Leerink Mkt Perform $35
Jun-25-20Downgrade Credit Suisse Outperform → Neutral
Apr-23-20Initiated Credit Suisse Outperform
Feb-24-20Reiterated H.C. Wainwright Buy $25 → $29
Jan-13-20Initiated SunTrust Buy $28
Dec-12-19Downgrade Deutsche Bank Buy → Hold
Sep-13-19Upgrade BofA/Merrill Neutral → Buy
Sep-12-19Upgrade JP Morgan Neutral → Overweight
Aug-12-19Initiated RBC Capital Mkts Outperform
Aug-12-19Initiated Morgan Stanley Overweight
Aug-12-19Initiated Guggenheim Buy
Nov-30-21 05:24AM  
Nov-22-21 03:59PM  
Nov-16-21 01:11PM  
Nov-10-21 11:00AM  
Nov-05-21 08:22AM  
Nov-04-21 04:24PM  
Nov-03-21 10:19AM  
Oct-19-21 06:29AM  
Oct-15-21 01:05PM  
Oct-14-21 10:08AM  
Oct-07-21 02:55PM  
Oct-01-21 08:00AM  
Sep-21-21 02:22PM  
Sep-20-21 05:03PM  
Sep-19-21 11:30AM  
Sep-17-21 08:39AM  
Sep-09-21 07:00AM  
Sep-03-21 12:49PM  
Aug-27-21 04:42AM  
Aug-18-21 01:00PM  
Aug-17-21 02:51PM  
Aug-11-21 11:00PM  
Aug-09-21 08:46AM  
Jul-21-21 12:58PM  
Jul-06-21 02:04PM  
Jul-05-21 11:40AM  
Jul-01-21 03:42AM  
Jun-28-21 03:30AM  
Jun-22-21 04:16PM  
Jun-21-21 03:46AM  
Jun-15-21 07:12PM  
Jun-14-21 03:57AM  
Jun-10-21 09:53AM  
Jun-07-21 04:01AM  
Jun-02-21 08:01AM  
Jun-01-21 06:27AM  
May-31-21 04:30AM  
May-25-21 03:57AM  
May-21-21 03:03PM  
May-20-21 08:14PM  
May-19-21 05:01PM  
May-17-21 04:34AM  
May-12-21 12:27PM  
May-11-21 02:50PM  
May-10-21 03:55AM  
May-07-21 03:01PM  
May-05-21 11:01AM  
May-03-21 02:58PM  
Apr-26-21 03:18AM  
Apr-20-21 06:34AM  
Apr-19-21 03:51AM  
Apr-13-21 04:44PM  
Apr-12-21 09:14AM  
Apr-09-21 04:00PM  
Apr-06-21 03:21AM  
Mar-30-21 01:21AM  
Mar-29-21 11:19AM  
Mar-22-21 05:15AM  
Mar-15-21 04:46AM  
Mar-10-21 05:37PM  
Mar-09-21 04:14AM  
Mar-08-21 03:54AM  
Mar-07-21 06:39AM  
Mar-02-21 03:31PM  
Mar-01-21 04:03AM  
Feb-26-21 04:12PM  
Feb-25-21 02:53PM  
Feb-23-21 09:00PM  
Feb-22-21 08:00AM  
Feb-19-21 12:41PM  
Feb-12-21 07:30AM  
Feb-11-21 11:12AM  
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumumab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Arzerra for treating CLL. Its products under development include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; tisotumab vedotin for treating cervical, ovarian, and solid cancers; HuMax-IL8 for treating advanced cancers; HexaBody-DR5/DR5, DuoBody-CD3x5T4, JNJ-63898081, JNJ-70218902, DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; and DuoBody-CD3xCD20 and DuoHexaBody-CD37 for treating hematological malignancies. The company's products under development also comprise Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; HuMax-IL8 for treating advanced cancers; JNJ-61186372 for the treatment of non-small-cell lung cancer; JNJ-63709178 and JNJ-67571244 to treat acute myeloid leukemia; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating Parkinson's disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with Immatics Biotechnologies GmbH to research and develop next-generation bispecific immunotherapies for treating multiple cancer indications; CureVac AG for the research and development of differentiated mRNA-based antibody products; AbbVie for the development of epcoritamab; and collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.